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A B S T R A C T
The French Society of Anesthesia and Intensive Care Medicine and the French Society of Intensive Care
edited guidelines focused on hospital-acquired pneumonia (HAP) in intensive care unit (ICU). The goal of
16 French-speaking experts was to produce a framework enabling an easier decision-making process for
intensivists. The guidelines were related to 3 specific areas related to HAP (prevention, diagnosis and
treatment) in 4 identified patient populations (COPD, neutropenia, postoperative and pediatric). The
literature analysis and the formulation of the guidelines were conducted according to the Grade of
Recommendation Assessment, Development and Evaluation methodology. An extensive literature
research over the last 10 years was conducted based on publications indexed in PubMedTM and
CochraneTM databases. HAP should be prevented by a standardized multimodal approach and the use of
§ Common guideline SFAR – SRLF of the French Society of Anaesthesia and Intensive Care Medicine, French Intensive Care Society, in collaboration with: ADARPEF and
GFRUP, Association of French-speaking Anaesthetists and Intensivists, French-speaking Group of Intensive Care and Paediatric emergencies.
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20%. Diagnosis relies on clinical assessment and microbiological findings. Monotherapy, in the absence
of risk factors for multidrug-resistant bacteria, non-fermenting Gram negative bacilli and/or increased
mortality (septic shock, organ failure), is strongly recommended. After microbiological documentation,
it is recommended to reduce the spectrum and to prefer monotherapy for the antibiotic therapy of HAP,
including for non-fermenting Gram-negative bacilli.
C 2017 The Authors. Published by Elsevier Masson SAS on behalf of Société française d’anesthésie et de
réanimation (Sfar). This is an open access article under the CC BY license (http://creativecommons.org/
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9214, PhyMedExp, université de Montpellier, 34295 Montpellier
cedex 5, France
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1. Introduction
Hospital-acquired pneumonia (HAP) is the most common
infection in the intensive care unit (ICU). This infection encom-
passes two different entities: pneumonia associated with mechan-
ical ventilation (ventilator-associated pneumonia or VAP) and
severe pneumonia developed during the hospital stay. The
incidence of VAP ranges from 1.9 to 3.8 per 1000 days of
mechanical ventilation in the US and exceeds 18 per 1000 days of
mechanical ventilation in Europe [1].
Nosocomial pneumonia is the most common infection in ICU,
when considering the timing of these infections. Non-ventilator
HAP occurs in patients admitted to the hospital for at least
48 hours and VAP is defined as occurring more than 48 hours after
the initiation of mechanical ventilation. Accurate data on their
epidemiology are limited by the lack of standardised diagnostic
criteria. In the US, the incidence of non-ventilator-HAP was 1.6%,
representing a rate of 3.63 per 1000 patient-days [2], while the
definition of VAP is not altered by considering time after admission
to the hospital and the incidence remain as mentioned above [1].
In the ICU, HAP is associated with an approximate mortality
rate of 20% [3]. However, the mortality attributable to HAP is
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probably higher in some specific populations such as patients with
chronic obstructive pulmonary disease (COPD) [1]. In other
populations such as trauma patients, HAP seems to have only a
minor effect on mortality [1]. Even though the direct impact of this
infection on mortality remains debated, it is nonetheless
associated with increased morbidity through increased duration
of mechanical ventilation (or decrease in ventilator-free days) and
increased ICU and hospital length-of-stay [1]. As a result, HAP is
also responsible for an overuse of healthcare resources (ventila-
tion, ICU and hospital beds and resources). Finally, it is associated
with increased costs related to hospital stay [4].
To date, the French Society of Anaesthesia and Intensive Care
Medicine (SFAR) and the French Society of Intensive Care (SRLF)
have not proposed guidelines focused on HAP. Sixteen French-
speaking experts were selected by an organising committee, itself
appointed by the guideline committees of each participating
society, following approval by their respective boards. Two
independent bibliographic experts analysed the literature of the
past 10 years in the field using pre-defined keywords.
Recent American and European guidelines have been published
(http://www.idsociety.org/Guidelines/Patient_Care/IDSA_Practice_
Guidelines/Infections_by_Organ_System/Lower/Upper_Respiratory/
Hospital-Acquired___Ventilator_-_Associated_Pneumonia_(HAP/
VAP)/). However, both the SFAR and SRLF wished to share their own
interpretation encompassing data from recently available publica-
tions. The boards of both societies designated an organising
committee, which appointed a panel of sixteen French-speaking
experts. Two members of the panel oversaw a literature search
using pre-defined keywords limited to the past decade.
2. Guidelines goals
The goal of these experts’ guidelines is to generate a framework
enabling an easier decision-making process for intensivists. The
group worked to produce a minimal number of guidelines in order
to highlight the key points to focus on in each area. When in doubt,
published data prevailed over expert opinion. The basic rules of
universal medical good practices — hygiene, antibiotic therapy,
comprehensive care — were considered as known and excluded
from the scope of the guidelines.
3. Definitions
The criteria to diagnose pneumonia are shown in Table 1. In
clinical practice, HAP is suspected when a patient presents with
fever, impaired oxygenation and suppurative secretions.
Non-ventilator HAP occurs after 48 h of hospital stay and VAP
occurs after 48 h of mechanical ventilation [5]. By definition,
neither is present nor incubating at hospital admission nor at the
onset of mechanical ventilation. The onset of either HAP or VAP
relative to hospital admission discriminates early pneumoniaTable 1
Criteria for defining pneumonia.
Radiological signs
Two successive chest radiographs showing new or progressive lung infiltrates
In the absence of medical history of underlying heart or lung disease, a single
chest radiograph is enough
And at least one of the following signs
Body temperature > 38,3̊C without any other cause
Leukocytes < 4000/mm3 or  12000/mm3
And at least two of the following signs
Purulent sputum
Cough or dyspnea
Declining oxygenation or increased oxygen-requirement or need for
respiratory assistance(< 5 days) from late pneumonia ( 5 days). Microbiologically
confirmed HAP was defined as the definitive identification of a
microorganism isolated from respiratory samples or in blood
cultures in a patient with suspected pulmonary infection.
4. Microbiological confirmation
The pathogens usually responsible for HAP are Enterobacte-
riaceae, Staphylococcus aureus, Pseudomonas aeruginosa and
Acinetobacter baumannii [1]. The infection is polymicrobial in
30% of cases. In early pneumonia, the most frequently identified
pathogens are methicillin susceptible S. aureus, Streptococcus
pneumonia and Haemophilus influenza [1].
Microbiological confirmation is a crucial step in the diagnosis of
HAP. Routinely, it is based on the qualitative or quantitative
cultures of respiratory samples. A pathogen is isolated from these
samples and identified in about 70% of suspected cases [1]. Other
biological tests can be carried out to support the microbiological
diagnosis such as blood cultures and antigenuria. Molecular
biology techniques applied to routine microbiology are still being
assessed and outside of the scope of these guidelines.
5. Method
5.1. General organisation
These guidelines are the result of the work provided by a panel
of experts, brought together by the SFAR and the SRLF. Each expert
was required to file a conflict-of-interest disclosure prior to
participation in establishing the guidelines. The stated mission was
to produce guidelines in three specific areas related to HAP:
prevention, diagnosis and treatment as well as the specificities
pertaining to different identified patient populations (COPD,
neutropenia, postoperative and pediatric).
The schedule of the group was defined upstream (Table 2). First,
the organisation committee and the guideline coordinators defined
the questions to be addressed by the panelists. It then appointed
experts in charge of each question. The questions were formulated
according to the Patients, Intervention Comparison Outcome
(PICO) format following a first meeting of the expert panel. The
literature analysis and the formulation of the guidelines were then
conducted according to the Grade of Recommendation Assess-
ment, Development and Evaluation (GRADE) methodology. A
level-of-evidence was defined for each reference cited according to
the type of study. This level-of-evidence could be re-evaluated
taking into account the methodological quality of the study.
Overall ‘‘strong’’ level-of-evidence resulted in formulating a
‘‘strong’’ recommendation (‘‘we recommend. . .’’ or ‘‘we recom-
mend not. . .’’; GRADE 1+ or 1). Overall moderate, weak or very
weak level-of-evidence resulted in formulating an ‘‘optional’’
recommendation (‘‘we suggest. . .’’, ‘‘we suggest not. . .’’; GRADE 2+
or 2). In the absence of supporting literature, a question could be
addressed by a recommendation under the form of an expert
opinion (‘‘the experts suggest that. . .’’). Recommendation propos-
als were presented to the entire panel and discussed one-by-one.
The goal was not to obtain consensus on all the proposals, but toTable 2
Guideline timeline.
December 5th 2016 Start-up meeting
March 6th 2017 Vote: first round
March 13th 2017 Post-vote deliberation meeting
April 1st 2017 Vote: second round
April 16th 2017 Amendment of two guidelines
April 28th 2017 Vote of the two amended guidelines
May 10th 2017 Guideline finalisation meeting
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recommendation was then evaluated by each expert rated using a
scale from 1 (complete disagreement) to 9 (complete agreement).
Collective rating was established according to a GRADE grid
methodology. To validate a recommendation on a criterion, at least
50% of experts had to have concordant opinions, while less than
20% of them had to have discordant opinion. For a recommenda-
tion to be strong, at least 70% of participants had to have
concordant opinions. Without strong agreement, recommenda-
tions were rephrased and resubmitted to reach a consensus.
5.2. Areas of guidelines
Three areas related to HAP were: prevention, diagnosis and
treatment with population-specific considerations. Four relevant
specific populations were considered in the guidelines analyses
(COPD, neutropenia, postoperative and pediatric). An extensive
literature research over the last 10 years was conducted based on
publications indexed in PubMedTM and CochraneTM databases. To
be considered for analysis, publications had to be written in English
or in French. It was decided ahead of the analysis to limit the
number of expert opinions and to not produce recommendations
that are not supported by literature. The analysis was focused on
recent data, according to decreasing hierarchical prioritisation of
data from meta-analyses of randomised controlled trials (RCTs) or
individual RCTs to observational studies. Study sample size and the
relevance of the research were considered at the level of each study.
5.3. Synthesis of results
The expert panel analyses and application of the GRADE method
led to 15 guidelines (and two specific guidelines for the pediatric
population) and four care protocols. Among the 15 formalised
guidelines for adults, three have a high level-of-evidence (GRADE
1+/) and 11 a low level-of-evidence (GRADE 2+/). For one
recommendation, the GRADE method could not be applied,
resulting an expert opinion. Both paediatric guidelines had a
weak level-of-evidence (GRADE 2). The four care protocols,
provided only as an indication, are based on expert opinions but
were submitted to the same rating and agreement process as the
guidelines. After two rounds of rating and one amendment, a
strong agreement was reached for all guidelines and protocols.
First area, PREVENTION:
Which HAP prevention approaches decrease morbidity and
mortality in ICU patients?
R1.1 – We recommend using a standardised multimodal
HAP prevention approach in order to decrease ICU patient
morbidity.
GRADE 1+, STRONG AGREEMENT
Evidence summary and rationale for the recommendation:
The implementation of standardised protocols is associated
with a decrease in ICU morbidity [6–10]. In before/after studies,
the implementation of a multimodal prevention strategy and
the adherence to a standardised multimodal approach are
associated with a decrease in HAP [11] and in the duration
of mechanical ventilation, provided that an early weaning
strategy is part of the approach [12]. Experts suggest increas-
ing prevention measures, and applying costly measures to
patients with a high risk of HAP and death, such as COPD
patients [13] or immunosuppressed patients.R1.1 Paediatrics – We suggest using a standardised multimod-
al approach aiming at preventing HAP in order to decrease
pediatric ICU patient morbidity.
GRADE 2+, STRONG AGREEMENT
Evidence summary and rationale for the recommendation:
Eight monocentric before/after or cohort studies suggest
that implementing and applying standardised HAP prevention
protocols in pediatric ICU patients are of interest in order
to reduce the occurrence of HAP and associated morbidity
[14–21].
R1.2 – In units where multidrug-resistant bacteria prevalence
is low (< 20%), we suggest applying routine selective diges-
tive decontamination using a topical antiseptic administered
enterally and a maximal 5-day course of systemic prophylactic
antibiotic to decrease mortality.
GRADE 2+, STRONG AGREEMENT
Evidence summary and rationale for the recommendation:
Meta-analyses of RCTs comparing selective digestive de-
contamination (SDD) to standard care show a significant
decrease in hospitality mortality, lengths of mechanical venti-
lation and HAP incidence in ICU patients [22]. In a sub-group
analysis from a multicentre trial, the effect of SDD on mortality
decrease was similar in medical and surgical patients [23]. In
the sub-group analysis of a meta-analysis of RCTs on pneu-
monia prevention strategies, the effect of SDD on the decrease
in mortality was only observed for strategies including a topical
antiseptic administered enterally and systemic prophylactic
antibiotic use [24]. The effect of SDD on the decrease in
mortality was greater in patients with high overall mortality,
demonstrating greater efficiency in the more critically ill [24]. In
the sub-group analysis of a large multicenter trial, SDD was
associated with a decrease in the acquisition of multidrug
resistant bacteria [25]. No link between SDD and the develop-
ment of bacterial resistance in ICU patients was shown in a
meta-analysis or in a randomised-controlled trial comparing
SDD to standard care [26]. It is probably best to limit the
duration of systemic antibiotic therapy in SDD protocols to
a maximum of 5 days, because prolonged antibiotic therapy
may lead to the emergence of multidrug-resistant bacteria [27].
The major studies that have demonstrated the efficiency of
SDD were conducted in environments where the prevalence of
multiresistant bacteria was low [25]. It is therefore recommen-
ded to follow the effects of this prevention strategy on the local
bacterial ecology on a regular basis. Consequently, we cannot
recommend such a strategy in units where the prevalence of
multiresistant bacteria is high.
R1.3 – Within a standardised multimodal HAP prevention
approach, we suggest combining some of the following
methods to decrease ICU patient morbidity:
 promote the use of non-invasive ventilation to avoid
tracheal intubation (mainly in post-operative digestive
surgery patients and in patients with COPD);
 favor orotracheal over nasotracheal intubation when
required;
 limit dose and duration of sedatives and analgesics
(promote their use guided by sedation/pain/agitation
scales, and/or daily interruptions);
 initiate early enteral feeding (within the first 48 hours of
ICU admission);
 regularly verify endotracheal tube cuff pressure;
 perform sub-glottic suction (every 6 to 8 hours) using an
appropriate endotracheal tube.
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Evidence summary and rationale for the recommendation:
Within multimodal HAP prevention approaches, methods
with an effect on patient morbidity should be favored, in
particular those with an effect on length of mechanical venti-
lation (ventilator-free days), ICU and hospital lengths-of-stay
and use of antibiotics.
For each of the methods proposed above, a significant
decrease in the risk of HAP and/or in the length of mechanical
ventilation and/or in ICU/hospital length-of-stay were reported
in:
 a meta-analysis of RCTs comparing non-invasive and
invasive ventilation [28], a RCT including patients in
postoperative digestive surgery patients of [29] and two
meta-analyses focused on weaning from mechanical
ventilation in patients with COPD [30,31];
 two before/after studies on the implementation of a
sedation protocol titrated by nurses [32,33];
 three meta-analyses of RCTs comparing early enteral
feeding (initiated before 48 h) to late feeding [34–36];
 RCTs comparing continuous to discontinuous monitor-
ing of tracheal intubation tube cuff pressures [37–39];
 two meta-analyses comparing sub-glottic suction to
standard care [40,41]. Tracheal intubation tubes with
sub-glottic suction may also have a positive cost-benefit
ratio;
 a randomised study comparing nasotracheal versus
orotracheal intubation [42].
R1.4 – Within a standardised multimodal HAP prevention
approach, we suggest not using the following methods to
decrease ICU patient morbidity:
 systematic early (< day 7) tracheotomy (except for
specific indications);
 anti-ulcer prophylaxis (except for specific indications);
 post-pyloric enteral feeding (except for specific indica-
tions);
 administration of probiotics and/or synbiotics;
 early systematic change of the humidifier filter (except
for specific manufacturer recommendations);
 use of closed suctioning systems for endotracheal
secretions;
 use of antiseptic-coated intubation tubes or with tubes
an ‘‘optimised’’ cuff shape;
 selective oro-pharyngeal decontamination (SOD) with
povidone-iodine;
 use of prophylactic nebulised antibiotics;
 daily skin decontamination using antiseptics.
GRADE 2, STRONG AGREEMENT
Evidence summary and rationale for the recommendation:
Although some of the abovementioned strategies have been
associated with significant decrease in the risk of HAP, no
reduction in morbidity (length of mechanical ventilation or ICU/hospital length-of-stay) or in mortality was demonstrated with
the use of these strategies individually. However, it is possible
that their combined use in prevention bundles may have some
beneficial effect on patient morbidity. However, there is lack of
available data in the literature to support this hypothesis.
Experts do not take position against these HAP prevention
techniques, but their first line use is not recommended, either
because of cost or potential adverse effects.
Thus, no beneficial impact in terms of HAP was found for the
following:
 early tracheotomy (before day-5 following ICU admis-
sion) compared to late tracheotomy (after day-14) apart
from specific indications [43,44];
 the use of oro-pharyngeal decontamination using
povidone-iodine (and potential toxic effects) [45];
 anti-ulcer prophylaxis use (apart from specific indica-
tion) compared to none [46];
 post-pyloric enteral compared to gastric enteral feeding
[47];
 enteral administration of probiotics or synbiotics [48–
50];
 enclosed tracheal suction systems compared to conven-
tional open tracheal suctioning [51];
 endotracheal intubation tubes lined/coated or incorpo-
rating silver or antiseptics compared to standard tubes
[52] and conical-shaped cuffs compared to standard
cuffs [53];
 nebulised prophylactic antibiotics during invasive
ventilation [24];
 systematic change of heat and moisture exchangers
[54,55];
 routine antiseptic baths for ICU patients [56,57].
R1.5 – In weaning of COPD patients from ventilation, we
suggest using non-invasive ventilation to reduce length of
invasive mechanical ventilation, incidence of HAP, morbidity
and mortality.
GRADE 2+, STRONG AGREEMENT
Evidence summary and rationale for the recommendation:
Invasive mechanical ventilation is the most important risk
factor for VAP. Several studies have analysed the role of non-
invasive ventilation (NIV) within the process of weaning from
mechanical ventilation. Their goals were the reduction of the
length of invasive mechanical ventilation and in VAP incidence.
Two meta-analyses [30,31] assessed the impact of NIV, as a
means of rapid weaning from invasive mechanical ventilation,
on the incidence of VAP.
In the first meta-analysis (9 studies, 632 patients with COPD),
NIV reduces the risks of mortality (risk ratio [RR]: 0.36; confi-
dence interval [CI] at 95% [0,24–0,56]; I2 = 0%), mechanical
ventilation weaning failure (RR: 0.52; CI 95% [0.36–0.74];
I2 = 0%) and VAP (RR: 0.22; CI 95% [0.13–0.37]; I2 = 3%) [30].
The second meta-analysis included 17 studies (959 patients
with COPD). It found a significant decrease in risk of mortality
(RR: 0.27; CI 95% [0.17–0.42]; I2 = 0%), mechanical ventilation
weaning failure (RR: 0.25; CI 95% [0.14–0.45]; I2 = 0%) and VAP
(RR: 0.18; CI 95% [0.12–0.27]; I2 = 0%) [31]. However, this meta-
analysis had several issues:
 several studies included in this meta-analysis were not
randomised;
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under 50;
 definition of VAP was not the same in every study.
Second area, DIAGNOSIS:
What methods to diagnose HAP should be used to decrease
ICU patient morbidity and mortality?
R2.1 – We suggest not using the clinical scores (CPIS, modified
CPIS) for diagnosing HAP.
GRADE 2, STRONG AGREEMENT
Evidence summary and rationale for the recommendation:
The performance of the clinical pulmonary infection score
(CPIS) in the diagnosis of pneumonia depends on the compar-
ator. Its sensibility and specificity vary from 60 to 80% com-
pared to microbiological samples obtained by bronchoalveolar
lavage [58–61]. The diagnostic performances are low when the
comparator is based on histology and pathology of post-
mortem lung biopsies in autopsy series [62]. The performance
of the CPIS depends on the pre-test probability of pneumonia
[63]. Nevertheless, CPIS variation over time may be useful in
pneumonia resolution [64] and antibiotic de-escalation
[65,66]. Initial CPIS at HAP onset has little value in predicting
patient outcomes, as compared to severity scores [67].
R2.2 – We suggest collecting microbiological airway samples,
regardless of type, before initiation of or any change in
antibiotic therapy.
GRADE 2+, STRONG AGREEMENT
Evidence summary and rationale for the recommendation:
A meta-analysis comparing different airway samples (endo-
tracheal aspirates, protected specimen brush and broncho-
scopic or blind bronchoalveolar lavage) and microbiological
culture methods (quantitative or not) found no significant
effect on patient outcomes (28-day mortality, ventilator-free
days, or length-of-stay) nor antibiotic treatment [68]. Therefore,
both sampling and culture methods are left to the discretion of
clinicians according to strategic choices at the unit, department
or institutional levels. There are little data specifically address-
ing the effect of sampling and culture methods on antibiotic
consumption or antibiotic-free days. One study found an
approximate increase of 2 antibiotic-free days with invasive
compared to non-invasive airway sampling [69]. In the absence
of any true gold standard, using post-mortem histology and
pathology findings upon autopsy as gold-standard surrogates
suggests a slightly greater diagnostic performance of quanti-
tative cultures, regardless of airway sample type. Indeed, in the
various autopsy case series summarised in the 2016 IDSA/ATS
guidelines [70] and in a dedicated meta-analysis [71]: (a)
quantitative culture, regardless of airway sample type had a
diagnostic odds-ratio (DOR) > 1, i.e. could establish a diagno-
sis in the presence of pneumonia, albeit with a high variation in
DOR ranging from close to 1 to much higher, whereas (b) semi-
or non-quantitative cultures had a low DOR, sometimes < 1, i.e.
a high probability of establishing a diagnosis in the absence of
pneumonia, and c) all positive likelihood ratios (LR+) were low,
close to 0.5, i.e. even in the case of high prevalence there would
be a low post-test probability (40–50%) of establishing a
diagnosis compared to pre-test suspected diagnosis regard-
less of culture method and thresholds. Therefore, there may be
an advantage to quantitative cultures in establishing the diag-
nosis and there may be an advantage to invasive sampling in
increasing antibiotic-free days. While obtaining airway sam-
ples should not delay initiation of antibiotic treatment in severecases and/or acute respiratory distress syndrome (c.f. R3.1) and
it remains essential to guiding and/or de-escalating antibiotic
therapy when microbiological identification is achieved (c.f.
R3.6).
In onco-hematology patients admitted to the ICU for respi-
ratory distress, lack of an established diagnosis is significantly
associated with increased mortality [72]. However, in these
patients the diagnosis is most often HAP, in two-thirds of the
cases [73]. In a randomised trial, 119 onco-hematology patients
admitted to the ICU for respiratory distress, among which 31%
were neutropenic, invasive lower respiratory tract sampling
[BAL] compared to non-invasive sampling was not associated
with increased risk of intubation nor increased mortality,
neither was there any difference in diagnostic yield between
sampling methods, around 80% [74].
R2.2 Paediatrics – We suggest collecting microbiological
airway samples, regardless of type, before initiation of or
any change in antibiotic therapy.
GRADE 2+, STRONG AGREEMENT
Evidence summary and rationale for the recommendation:
Labenne et al. compared protected distal brush and blind
bronchoalveolar lavage samples for VAP diagnosis [75]. Of the
103 patients, 29 were diagnosed with VAP. The combination of
brushing with culture of the blind bronchoalveolar lavage
sample and a bacteriological index (BI) resulted in a sensitivity
(Se) of 90% and a specificity (Sp) of 88% for VAP diagnosis.
Gauvin et al. compared several types of microbiological sam-
ples and qualitative or quantitative culture methods for VAP
diagnosis, using the 1988 CDC VAP diagnosis criteria [76]. The
best performing method for the diagnosis of VAP was the
bacteriological index, BI > 5 (Se 78%, Sp 86%, positive predic-
tive value, PPV of 70%, and negative predictive value, NPV of
90%) but the number of VAP was low. Sachdev et al. prospec-
tively found in 30 patients a superiority of protected distal
samples compared to endotracheal aspirates to diagnose HAP
[77]. The same authors confirmed the excellent reproducibility
of protected distal samples in 34 children with VAP, both for the
cellular analysis and bacteriological diagnosis [78]. From
335 samples obtained prospectively in 61 children, Willson
et al. reported the lack of usefulness of tracheal samples for
VAP diagnosis, suggesting that the distinction between colo-
nization and infection is challenging [79].
To summarise, since endotracheal tube and upper airway
colonisation occur rapidly following intubation, the use of
protected distal samples may provide superior specificity to
endotracheal aspirates. In the absence of any demonstrated
impact on outcomes, the choice of airway sampling and culture
methods depends on the environment, institutional and de-
partmental strategic choices, taking into account the appropri-
ate threshold of the chosen method when paired with
quantitative cultures.
R2.3 – We suggest not measuring plasma or alveolar levels of
procalcitonin or soluble TREM-1 to diagnose HAP.
GRADE 2, STRONG AGREEMENT
Evidence summary and rationale for the recommendation:
Eight studies have assessed the contribution of measuring
procalcitonin (PCT) plasma concentrations to the diagnosis of
HAP, on their own or in combination with clinical criteria [80–
87]. A total of 589 patients were included for a pneumonia
prevalence of 55% and the following test characteristics:
Se = 54% (48–59%), Sp = 67% (51–73%), PPV = 67% and
NPV = 54%. The positive likelihood ratio (LR+) was 1.65 and
negative likelihood ratio (LR) 0.68. These performances
are insufficient to contribute to the diagnosis decision
process. Diagnostic test thresholds varied, ranging from
0.15 to 3.9 ng/mL.
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trations of the soluble form of the Triggering Receptor Expres-
sed on Myeloid cells-1 (sTREM-1) to the diagnosis of HAP [87–
93]. A total of 317 patients were included for a prevalence of
48%. The sTREM-1 test characteristics were: Se = 83% (76–89%)
and the Sp = 77% (69–83%), resulting in a PPV of 77% and a NPV
of 83%n, a LR+ of 3.56 and LR of 0.22. Even if these perfor-
mances seem interesting, mainly for the exclusion of the
diagnosis, the diagnostic thresholds varied widely, ranging
from 5 to 900 pg./Mr. This could be explained by different and
non-standardised dosage techniques, excluding the possibility
of using this test in clinical practice at the moment.
It is surprising to observe the low number of patients
included in these biomarker studies (PCT or sTREM-1), con-
tributing to their poor robustness.
Third area, TREATMENT:
What therapeutic options for HAP should be used to
decrease ICU patient morbidity and mortality?
R3.1 – We suggest immediately collecting samples and initi-
ating antibiotic treatment taking into consideration risk fac-
tors for multidrug resistant bacteria in patients with suspected
HAP and haemodynamic or respiratory compromise (shock or
acute respiratory distress syndrome) or frailty such as immu-
nosuppression.
GRADE 2+, STRONG AGREEMENT
Evidence summary and rationale for the recommendation:
The urgent need for antibiotics in septic shock does not fall
within the scope of these guidelines. Clinicians should consult
current guidelines on the management of septic shock. The
immunosuppressed patients receive specific treatment.
In HAP, no RCT has compared a strategy based on early
empirical antibiotic therapy to definitive antibiotic therapy after
pathogen isolation, identification and susceptibility testing on
patient outcomes, with stratification on pre-test diagnosis
probability and clinical severity. However, several observation-
al studies and a meta-analysis have shown that inappropriate
initial antibiotic therapy, i.e. ineffective according to suscepti-
bility testing of the causal pathogen, was associated with
worse outcomes (length of mechanical ventilation, length-
of-stay and mortality), suggesting that the appropriate empiri-
cal antibiotic therapy is associated with improved outcomes
[94–99].
R3.2 – We recommend treating HAP in mechanically-ventilated
immunocompetent patients empirically by a monotherapy, in
the absence of risk factors for multidrug-resistant bacteria,
non-fermenting Gram negative bacilli and/or increased mor-
tality (septic shock, organ failure).
GRADE 1+, STRONG AGREEMENT
Evidence summary and rationale for the recommendation:
We identified three RCTs published over the last ten years
[100–102] and a meta-analysis [103] of these three studies
(including a prior study [104]) including 1163 patients. They
compared monotherapy vs. combined therapy. All studies
reported on the impact of combined therapy on mortality.
Only two reported on clinical cure and the incidence of adverse
effects [100,104]. No difference between monotherapy and
combined therapy was found in terms of mortality (odds ratio
[OR]: 0.97; IC 95% [0.73–1.30]), clinical cure (OR: 0.88; IC 95%
[0.56–1.36]), ICU length-on-stay (OR: 0.65; IC 95% [0.07–1.23]),
or adverse effects (OR: 0.93; IC 95% [0.68–1.26]). The moderate
methodological quality mainly comes from the inaccuracy of
the results and/or the heterogeneity of studies included in the
meta-analysis. We decided to grade this recommendation as
strong in spite of a moderate overall methodological qualitybecause of: a convergence of published studies towards the
absence of benefit of combined therapy, the high relevance of
the endpoints studied in the studies, and data demonstrating
adverse effects of combined therapy in terms of increased
toxicity, emergence of resistance and cost [105,106]. However,
several elements issues remain:
 the methodological quality of analysed trials in the
meta-analysis ranges from moderate (mortality, ICU
length-of-stay, adverse effects) to very low (clinical
cure);
 the number and size of studies are limited. In fact, if the
mortality analysis is based on four studies (n = 1163),
the other judgment criteria are analysed using two
studies (n = 350 for clinical recovery; n = 921 for adverse
effects; n = 813 for ICU length-of-stay);
 observational studies and a few controlled studies have
suggested that in the presence of multidrug-resistant
bacteria [102] or non-fermenting Gram-negative bacilli
[107–110], the risk of an inappropriate empirical
antibiotic therapy is higher, resulting in higher mortali-
ty, and ICU or hospital length-of-stay.
Empirical combined therapy increases the rate of appropri-
ate empirical antibiotic therapy in VAP caused by multidrug-
resistant bacteria [102,109]. It is therefore important to sys-
tematically screen for risk factors to develop an infection to or
the carrying of multidrug-resistant (MDR) bacteria or non-
fermenting Gram-negative bacilli, mainly Pseudomonas aeru-
ginosa.
The established risk factors for Pseudomonas aeruginosa
pneumonia are COPD, bronchiectasis and cystic fibrosis. The
risk factors associated with MDR bacteria airway colonisation
and HAP are [70]:
 antibiotic therapy in the previous 90 days;
 a hospital stay of more than 5 days prior to suspected
HAP;
 renal replacement therapy requirement during HAP;
 septic shock;
 ARDS.
In the presence of at least one of these risk factors, combined
empirical therapy is indicated. However, after pathogen iden-
tification and susceptibility testing, no study has shown that
pursuing combined therapy remains beneficial in VAs, includ-
ing VAP due to Pseudomonas aeruginosa [70,103,111].
 Finally, for a given patient, a predictable mortality rate
above 25% probably remains an indication for combined
empirical antibiotic therapy. In a meta-analysis includ-
ing observational and randomised studies, a benefit to
combined therapy is found in terms of mortality (31% vs.
41%; hazard ratio: 0.71; IC 95% [0.57–0.89]) in patients
with sepsis due to lung infection [112]. These results
have to be taken cautiously since they depend on the
spectrum of the primary antibiotic; combination thera-
py yielded no advantage when the primary antibiotic
was itself a broad-spectrum antibiotic. This meta-
analysis also showed that combined therapy in patients
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deleterious consequences. The recommendation is
therefore quite limited since it only applies to immuno-
competent patients, without any risk factor for multi-
drug-resistant bacteria, and at low risk of mortality. In
the presence of one or several of such risk factors,
empirical combined therapy is probably indicated
before pathogen identification and susceptibility testing
results are available.
R3.3 – The experts suggest not systematically directing em-
piric antibiotic therapy against methicillin-resistant Staphylo-
coccus aureus in the treatment of HAP.
EXPERTS OPINION, STRONG AGREEMENT
Evidence summary and rationale for the recommendation:
A study randomising patients treated empirically with an
antibiotic regimen including or not an antibiotic active against
methicillin-resistant Staphylococcus aureus (MRSA) did not
show any difference between the two strategies in terms of
length-of-stay and mortality [113]. An observational and pro-
spective study found a decrease in mortality in patients who
had received an empirical antibiotic therapy including vanco-
mycin [114]. The prevalence of MRSA VAP (15%) supports this
result. The literature suggests that inappropriate empirical
antibiotic therapy plays a major part in the mortality of patients
with MRSA HAP [115]. However, a study found an increase in
ICU length-of-stay in patients with MRSA HAP, independently
from the adequacy of the empirical treatment [116]. The ade-
quacy of the empirical antibiotic therapy is a critical factor for
survival and the length-of-stay [113,117]. A randomized con-
trolled study highlighted an increase in MRSA emergence in
patients treated empirically with vancomycin [113]. This
encourages highly selecting patients to be treated empirically
with an antibiotic directed against MRSA.
In conclusion, only one study conducted in an environment
in which the prevalence of MRSA was high (15% of VAP
episodes) showed an association between the empirical use
of an antibiotic against MRSA and an improvement in HAP
outcomes. There is therefore no rationale for the systematic
empirical use of an antibiotic against MRSA in France, the
prevalence being lower than 3% [118]. However, the consid-
eration of the local ecology is important. Some risk factors
encourage including an antibiotic active against MRSA in the
empirical antibiotic therapy of HAP, without the possibility to
establish an exhaustive list (experts’ opinion):
 high local prevalence of MRSA;
 recent colonisation by MRSA;
 chronic skin lesions;
 chronic renal replacement therapy.
R3.4 – We suggest reducing the spectrum and preferring
monotherapy for the antibiotic therapy of HAP after microbi-
ological documentation, including for non-fermenting Gram-
negative bacilli.
GRADE 2+, STRONG AGREEMENT
Evidence summary and rationale for the recommendation:
Both reducing the spectrum and preferring a monotherapy
for the antibiotic therapy of HAP after documentation are
encompassed by the term ‘‘de-escalation’’. De-escalation is
possible as soon as the microbiological results are obtained.
Nine studies and a meta-analysis address this question. A
meta-analysis by Silva et al. did not draw conclusions regard-ing safety and efficacy of de-escalation [119]. Two randomized
open controlled studies compared mortality in a ‘‘de-escala-
tion’’ compared to a ‘‘control’’ group [113,120]. These two
studies did not find any significant difference in overall mor-
tality between the two strategies.
Kim et al. found an increase in mortality in the de-escalation
group for MRSA documented VAP. Seven observational stud-
ies have also compared the de-escalation to the maintenance
of the initial antibiotic regimen in terms of mortality. In three
prospective studies [114,121,122] and a retrospective study
[123], mortality decreased in the de-escalation group. Finally,
three retrospective studies [124–127] did not find any mortality
difference between the two strategies. The ICU length-of-stay
was prolonged (non-inferiority not obtained) in the de-escala-
tion group of a randomised study [120]. On the contrary, a
prospective observational study found an association between
a shorter ICU length-of-stay and de-escalation [122].
The risk of relapse associated with de-escalation remained
unchanged in two observational studies [126,127] and in-
creased in one randomised [120] and one retrospective study
[124]. In a randomised study, de-escalation was associated
with an increase in the duration of antibiotic treatment, even
though less active antibiotics against Pseudomonas aerugi-
nosa were used in the de-escalation group [120]. However, it is
important to note that in this study, VAP represented 48% of
included patients [120]. A sub-group analysis on the 56 VAPs
did not find differences in these outcomes.
In summary, no data allows to confirm that a de-escalation
strategy is associated with increased mortality. It is impossible
to conclude concerning the risk of increased length-of-stay,
antibiotic consumption and infectious relapse. However, in a
strategy of antibiotic stewardship, preservation of large spec-
trum antibiotics, and preventing the emergence of multidrug-
resistant bacteria, and in the absence of proven deleterious
effects on survival, de-escalation strategy seems reasonable.
R3.5 – We recommend not prolonging for more than 7 days the
antibiotic treatment for HAP, including for non-fermenting
Gram-negative bacilli, apart from specific situations (immu-
nosuppression, empyema, necrotising or abscessed pneumo-
nia).
GRADE 1, STRONG AGREEMENT
Evidence summary and rationale for the recommendation:
There are two meta-analyses comparing treatment dura-
tions of 8 days or less to 9 days or more [128,129]. Data are only
available in the area of VAP. The first of these meta-analyses
relies on six RCTs, including a meeting summary, which was
not reported here [130–134]. This meta-analysis included
508 patients. Mortality (28-day, ICU and hospital), length-of-
stay and of mechanical ventilation did not change according to
treatment duration. Patients in the short-course group had a
mean increase in antibiotic-free days at day 28 of 4.02 days; IC
95% = 2.26 to 5.78 days), and a decrease in secondary infec-
tious episodes due to multidrug-resistant bacteria. However,
this meta-analysis highlighted a trend towards an increase of
the number of relapses and a significant increase in the number
of pneumonia relapses in patients with a non-fermenting
Gram-negative bacillus infection. The weight of a single mul-
ticenter study was essential to explain this result [130]. The
increase in relapses was not associated with increased mor-
tality. The second meta-analysis found similar results based on
three randomised studies including 883 patients
[130,132,133]. However, the increased risk of relapses for
VAP linked to non-fermenting Gram-negative bacilli was not
confirmed. No medico-economic study compared the costs
and efficacy of shorter and longer antibiotic courses.
In summary, there is no benefit to prolonged courses of
antibiotic therapy (longer than 7 days) for VAP. A shorter
course reduces the exposure to antibiotics and infectious
relapses to multidrug-resistant bacteria, albeit with a potential
risk of relapse of VAP associated with non-fermenting Gram-
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patients (Human Immunodeficiency Virus, neutropenia, immu-
nosuppressants, corticosteroids > 0.5 mg/kg/d for more than a
month, cystic fibrosis) and situations known to require pro-
longed antibiotic therapy such as empyema, necrotising or
abscessed pneumonia [131; 133, 135]. A shorter antibiotic
course has yet to be evaluated in these specific patient popu-
lations or situations and this recommendation may therefore
not be applied to them.
R3.6 – We suggest administering nebulised colimycin (sodium
colistimethate) and/or aminoglycosides in documented HAP
due multidrug-resistant Gram-negative bacilli documented
pneumonia established as sensitive to colimycin and/or ami-
noglycoside, when no other antibiotics can be used (based on
the results of susceptibility testing).
GRADE 2+, STRONG AGREEMENT
Evidence summary and rationale for the recommendation:
Among the studies published over the last 10 years, four
RCTs [135–138] (with a low to moderate methodological quali-
ty) out of seven [135–141] concluded to the favorable impact of
nebulised antibiotics in terms of clinical [135,138] and micro-
biological [136–138] cure in VAP. Following these results, three
meta-analyses [70,142,143] (with a very low to moderate
methodological quality) concluded to a benefit of nebulised
antibiotics for clinical cure (RR: 1.29 CI 95% [1.13–1.47]) [70];
(RR: 1.57; CI 95% [1.14–2.15]) (143); (RR: 1.23; CI 95% [1.05–
1.43]) (144)). Only one meta-analysis concluded to the superi-
ority of nebulised antibiotics in terms of microbiological re-
sponse [142]. Two positive studies (in terms of clinical and
microbiological cure for the first [138] and microbiological cure
for the second [136]) were not included in the meta-analyses.
No meta-analysis has demonstrated a favorable effect of
nebulised antibiotics on mortality. However, Valachis et al.
found a benefit on sepsis-induced mortality (RR: 0,58; CI 95%
[0,34–0,96]; very weak methodological quality).
The benefits in terms of decrease in the emergence of
multidrug-resistant bacteria were shown in five studies
[136–139,144], of which four were randomised and controlled
[136–139]. The decrease in the emergence of multidrug-resis-
tant bacteria during treatment was significant in three studies
[136–138]. The effect on the decrease in the emergence of
multirdrug-resistant bacteria is to be taken into account accord-
ing to the epidemiological context. In spite of thee favorable
meta-analyses, it is important to note that:
 the investigation area is limited to VAP due to Gram-
negative bacilli, mainly Enterobacteriaceae or non-
fermenting Gram-negative bacilli, implying a treatment
with amikacin and/or colimycin treatment. In fact, six of
the seven randomised and controlled studies tested the
administration of nebulised aminoglycosides. The
pathogens responsible for VAP were mainly [137,138]
or exclusively [135,136,139–141] Gram-negative bacilli.
Three of these seven studies specifically tested the
efficacy of nebulised antibiotics in VAP caused by
Pseudomonas spp. and Acinetobacter spp [135,139,141];
 there is a heterogeneity among the controlled studies
included in the three meta-analyses concerning the
modalities of nebulisation, dosing of nebulised anti-
biotics, concomitant systemic antibiotics, and non-
consensual composite criteria for clinical and/or micro-
biological cure;
 the meta-analysis of Valachis et al. included seven
observational studies and one randomised controlled
study, leading to an assessment of its level ofmethodological quality, varying from weak to very
weak, according to the studied judgment criteria [142];
 the literature does not support the superiority of an
empirical combined therapy containing either of the
two antibiotics administered by nebulisation;
 deleterious effects of nebulised antibiotics have been
described, mainly in the most hypoxemic patients [145].
In terms of microbiological eradication of multidrug-resis-
tant Gram-negative bacilli, nebulised antibiotics have proven
superior in two controlled studies [137,138] and non-inferior in
one observational [144] and one controlled study [141]. In this
context, a meta-analysis including six randomized controlled
studies and five observational studies concluded to a thera-
peutic benefit of nebulised compared to systemic antibiotics
on mortality (RR: 0.64; CI 95% [0.44–0.94]). A decrease in the risk
of nephrotoxicity was also observed using nebulisation (RR:
0.33; CI 95% [0.54, 0.12]). Consequently, despite the weak
methodological quality of this meta-analysis, due to heteroge-
neity and given:
 studies assessing the eradication kinetics of bacteria
causing VAPs [136–139,144] and PK/PD parameters
[136,140] have shown rapid bactericidal effect, through
the high colimycin and/or aminoglycoside concentra-
tions obtained at the alveolar level, with nebulised
antibiotics [146–148];
 experimental data showing that pulmonary penetration
of aminoglycosides and colimycin is null or very weak
following systemic administration [149–151], the ben-
efit-risk balance of nebulised antibiotics is probably
favorable for documented VAP due to multidrug-
resistant Gram-negative bacilli that are susceptible to
colimycin and/or aminoglycosides. The specifics of the
equipment used (vibrating plate or ultrasonic nebuliza-
tion chambers, position of the nebulisation chamber in
the ventilation circuit, specific formulations of nebulised
antibiotics) and the specific modalities of mechanical
ventilation during nebulisation require prior training of
teams, in order to reproduce the conditions described in
the positive studies.
R3.7 – We recommend not administering statins as adjuvant
treatment for HAP.
GRADE 1, STRONG AGREEMENT
Evidence summary and rationale for the recommendation:
Five randomised controlled studies [152–156] included in a
meta-analysis (n = 867) [157]) and one observational study
(n = 349) [158] were analysed. Among these studies, three
controlled studies included patients with HAP outside of the
ICU [153,154,156], two controlled studies [152,155] and an
observational study [158] included patients admitted to the
ICU and requiring mechanical ventilation [155,158] or not
[152]. Papazian et al. [155] and Bruyè re et al. [158] included
patients with sepsis from all causes, in whom pneumonia
represented approximately 50% of patients. No benefits in
terms of mortality, ICU or hospital length-of-stay, and in length
of mechanical ventilation were demonstrated with statins.
Given the overall high methodological quality (high in the
controlled studies [152–156] and in the meta-analysis [157]),
the importance of the tested judgment criteria, the relative
diversity of population (outside ICU, ICU, mechanically-venti-
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or simvastatin, low or high dose), we obtain a strong recom-
mendation covering a large application range. The sub-group
of 27 observational studies of the meta-analysis is the only one
to suggest a beneficial effect of statins on mortality [157]. High
heterogeneity, publication bias and the limits to the formats of
observational studies published over several decades limit the
relevance of this result. This effect was therefore not retained
as open to interpretation by the experts. Finally, it is important
to note the high tolerance of the treatment by statins, regard-
less of molecule or dose, without any increase in the risk of
rhabdomyolysis or hepatic cytolysis.
We did not identify any studies published on the eventual
role of corticosteroids administered for HAP in ICU patients.
The only study published that has tested anti-lipopolysaccha-
ride monoclonal antibodies as an adjuvant treatment is a
posteriori analysis [159] of a previous study of the Phase IIA
[160] comparing 17 patients in treatment and 17 patients using
placebos. The post-hoc characteristic, the small study sample
size, added to the heterogeneous demographic characteristics
between groups, and the non-crucial judgment criteria (clinical
resolution of pneumonia), do not allow concluding to an effect
of this type of treatment. No recommendation was formulated
on the adjuvant administration of these adjuvant treatments
for HAP in adult ICU patients.
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Appendix A
Protocol 1 suggested by experts: Multimodal healthcare
associated pneumonia prevention protocol (EXPERTS’ OPINION)
Multimodal healthcare associated pneumonias prevention
protocol
1 – Favour non-invasive ventilation (NIV) (mainly following
digestive surgery and for COPD patients)
When invasive ventilation is required:
2 – Apply* a selective digestive decontamination protocol
with prophylactic systemic antibiotic treatment < 5 days
*If the prevalence of multiresistant bacteria is low (< 20%).
3 – Associate some of the following methods (1st line):
 favour the use of NIV to prevent intubation;
 limit dose and duration of sedatives and analgesics associated
with mechanical ventilation;
 initiate early enteral feeding;
 regularly verify endotracheal tube cuff pressures;
 perform sub-glottic suction (/6-8 hours) using an appropriate
endotracheal tube;
 favour the orotracheal route for intubation.
NB: The association of head of bed elevation < 30̊ and/or
oropharyngeal decontamination with 0.12 or 0.2% chlorhexidinecould be proposed in association to these measures, despite low
efficiency, because they do not cost much and are well-tolerated.
4 – Avoid using the following methods:
 systematic early tracheotomy (apart from specific indications);
 anti-ulcer prophylaxis (apart from specific indications);
 post-pyloric enteral feeding (apart from specific indications);
 probiotics;
 systematic early changing of humidifier filters (apart from a
recommendation from the manufacturer);
 closed endotracheal suction systems;
 the use of intubation tubes lined/coated or incorporating silver
or antiseptics, or with an ‘‘optimised’’ cuff shape;
 oropharyngeal decontamination using povidone-iodine;
 prophylactic nebulized antibiotics;
 daily skin decontamination using antiseptics.
Protocol 2 suggested by experts: Selective digestive decon-
tamination (EXPERTS’ OPINION)
Oro-pharyngeal application ( 4/day, until tracheal extuba-
tion) of a paste or gel containing
 polymyxin E (2%);
 tobramycin (2%);
 amphotericin B (2%).
+
Administration ( 4/day, until tracheal extubation) through
a nasogastric tube of 10ml of a suspension containing
 100 mg polymyxin E;
 80 mg tobramycin;
 500 mg amphotericin B.
+
Intravenous administration of a prophylactic antibiotic
treatment during 48 to 72 hours for patients who do not
require curative antibiotic therapy
 cefazolin 1 g  3/d*;
 In case of allergy to cephalosporins:
 ofloxacin 200 mg  2/d*;
 ciprofloxacin 400 mg  2/d*.
(*dosages in the absence of renal failure, provided for information
purposes only)
Preparation for selective digestive decontamination (pro-
vided for information purposes only)
Oral gel
(jar 125 mL)
Suspension
(bottles 15 mL)
Polymyxin E
Gentamicin
Amphotericin B
Sterile water
Methylcarboxycellulose
Methylparahydroxybenzoate
Propylene glycol
Menthol alcohol
4 g
4 g
4 g
134 mL
6 g
0.3 g
50 mL
6 mL
1 g
0.8 g
5 g
100 mL
Protocol 3: suggested diagnostic procedure (EXPERT’S OPINION)
*N.B.: In case of radiographic doubt, it is possible to search for infiltrates using non-contrast thoracic computed tomography or consolidation
using ultrasound.
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Protocol 4 suggested by experts: treatment options (EXPERTS’ OPINIONS)
Nosological framework Therapeutic class Antimicrobials Dosing regimena
Early pneumonia < 5 days b-lactam, inactive against
P. aeruginosa
Amoxicillin/clavulanic acid 3 to 6 g/d
Absence of septic shock 3rd gen. cephalosporin,
cefotaxime
3 to 6 g/d
Absence of MDR bacteria risk
factors
In case of allergy to b-lactam:
levofloxacin
500 mg  2/d
Early pneumonia < 5 days b-lactam, inactive against
P. aeruginosa
Amoxicillin/clavulanic acid 3 to 6 g/d
Presence of septic shock 3rd gen. cephalosporin,
cefotaxime
3 to 6 g/day
Absence of MDR bacteria risk
factors
+ Aminoglycosideb or +
Fluoroquinolone
Example: gentamicin or
Example: ofloxacin
In case of allergy to b-lactam:
Levofloxacin +
Gentamicin
8 mg/kg/d
200 mg  2/d
500 mg  2/d
8 mg/kg/d
Late pneumonia  5 days
or
presence of other risk factors for
nonfermenting Gram-negative
bacillie
b-lactam, ACTIVE against
P. aeruginosa
Ceftazidime
or
3 to 6 g/d
Cefepime
or
4 to 6 g/d
Piperacillin-tazobactam
or in case of ESBLc
16 g/d
Imipenem-cilastatine
or
3 g/d
+
Meropenem
+
3 to 6 g/d
Aminoglycosideb
or
Amikacind
or
30 mg/kg/d
Fluoroquinolone Ciprofloxacin 400 mg  3/d
In case of allergy to b-lactam
Aztreonam
+
3 to 6 g/d
Clindamycin 600 mg  3 to 4/d
Any presentation, presence of
MRSA risk factorsf
Add agent active against
MRSA
Vancomycin
or
15 mg/kg loading followed
by 30 to 40 mg/kg/d continuous
Linezolid 600 mg  2/d
a Doses are given for information purposes only in patients with normal renal function and standard weight.
b Favour the use of aminoglycosides over fluoroquinolones to limit emergence of MDR bacteria.
c According to the guidelines’ criteria ‘‘Reduce de use of antibiotics in intensive care unit’’.
d Favour the use of amikacin over gentamicin due to enhanced efficacy against non-fermenting Gram-negative bacilli.
e Risk factors for non-fermenting Gram-negative bacilli: antibiotic therapy in the previous 90 days, prior hospital stay of more than 5 days,
renal replacement therapy requirement during pneumonia, septic shock, acute respiratory distress syndrome.
f Methicillin-resistant Staphylococcus aureus (MRSA) risk factors: high local prevalence of MRSA, recent colonisation by MRSA, chronic skin
lesions, chronic renal replacement therapy.
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[37] Lorente L, Lecuona M, Jiménez A, Lorenzo L, Roca I, Cabrera J, et al. Continuous
endotracheal tube cuff pressure control system protects against ventilator-
associated pneumonia. Crit Care 2014;18(2):R77.
[38] Valencia M, Ferrer M, Farre R, Navajas D, Badia JR, Nicolas JM, et al. Automatic
control of tracheal tube cuff pressure in ventilated patients in semirecumbent
position: a randomized trial. Crit Care Med 2007;35(6):1543–9.
[39] Nseir S, Zerimech F, Fournier C, Lubret R, Ramon P, Durocher A, et al.
Continuous control of tracheal cuff pressure and microaspiration of gastric
contents in critically ill patients. Am J Respir Crit Care Med 2011;184(9):
1041–7.
[40] Caroff DA, Li L, Muscedere J, Klompas M. Subglottic secretion drainage and
objective outcomes: a systematic review and meta-analysis. Crit Care Med
2016;44(4):830–40.
[41] Muscedere J, Rewa O, McKechnie K, Jiang X, Laporta D, Heyland DK. Subglottic
secretion drainage for the prevention of ventilator-associated pneumonia: a
systematic review and meta-analysis. Crit Care Med 2011;39(8):1985–91.
[42] Holzapfel L, Chastang C, Demingeon G, Bohe J, Piralla B, Coupry A. A random-
ized study assessing the systematic search for maxillary sinusitis in naso-
tracheally mechanically ventilated patients. Influence of nosocomial
maxillary sinusitis on the occurrence of ventilator-associated pneumonia.
Am J Respir Crit Care Med 1999;159(3):695–701.
[43] Siempos II, Ntaidou TK, Filippidis FT, Choi AM. Effect of early versus late or no
tracheostomy on mortality and pneumonia of critically ill patients receiving
mechanical ventilation: a systematic review and meta-analysis. Lancet Res-
pir Med 2015;3(2):150–8.
[44] Young D, Harrison DA, Cuthbertson BH, Rowan K. TracMan Collaborators.
Effect of early vs late tracheostomy placement on survival in patients
receiving mechanical ventilation: the TracMan randomized trial. JAMA
2013;309(20):2121–9.
[45] Seguin P, Laviolle B, Dahyot-Fizelier C, Dumont R, Veber B, Gergaud S, et al.
Study of Povidone Iodine to reduce pulmonary infection in head trauma and
cerebral hemorrhage patients (SPIRIT) ICU Study Group; AtlanRéa Group. Effect
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[62] Fàbregas N, Ewig S, Torres A, El-Ebiary M, Ramirez J, de La Bellacasa JP, et al.
Clinical diagnosis of ventilator associated pneumonia revisited: comparative
validation using immediate post-mortem lung biopsies. Thorax
1999;54(10):867–73.
[63] Lauzier F, Ruest A, Cook D, Dodek P, Albert M, Shorr AF, et al., Canadian Critical
Care Trials Group. The value of pretest probability and modified clinical
pulmonary infection score to diagnose ventilator-associated pneumonia. J
Crit Care 2008;23(1):50–7.
[64] Luna CM, Blanzaco D, Niederman MS, Matarucco W, Baredes NC, Desmery P,
et al. Resolution of ventilator-associated pneumonia: prospective evaluation
of the clinical pulmonary infection score as an early clinical predictor of
outcome. Crit Care Med 2003;31(3):676–82.
[65] Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL. Short-course empiric
antibiotic therapy for patients with pulmonary infiltrates in the intensive
care unit. A proposed solution for indiscriminate antibiotic prescription. Am J
Respir Crit Care Med 2000;162(2 Pt 1):505–11.
[66] Luyt CE, Chastre J, Fagon JY. Value of the clinical pulmonary infection score for
the identification and management of ventilator-associated pneumonia.
Intensive Care Med 2004;30(5):844–52.
[67] Larsson J, Itenov TS, Bestle MH. Risk prediction models for mortality in
patients with ventilator-associated pneumonia: A systematic review and
meta-analysis. J Crit Care 2017;37:112–8.
[68] Berton DC, Kalil AC, Teixeira PJ. Quantitative versus qualitative cultures of
respiratory secretions for clinical outcomes in patients with ventilator-
associated pneumonia. Cochrane Database Syst Rev 2014;(10):CD006482.
[69] Fagon JY, Chastre J, Wolff M, Gervais C, Parer-Aubas S, Stéphan F, et al.
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[118] Santé publique France. Surveillance des infections nosocomiales en réani-
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Reliability of mini-bronchoalveolar lavage for the measurement of epithelial
lining fluid concentrations of tobramycin in critically ill patients. Intensive
Care Med 2007;33(9):1519–23.
[147] Carcas AJ, Garcı́a-Satué JL, Zapater P, Frı́as-Iniesta J. Tobramycin penetration
into epithelial lining fluid of patients with pneumonia. Clin Pharmacol Ther
1999;65(3):245–50.
[148] Luyt CE, Clavel M, Guntupalli K, Johannigman J, Kennedy JI, Wood C, et al.
Pharmacokinetics and lung delivery of PDDS-aerosolized amikacin (NKTR-
061) in intubated and mechanically ventilated patients with nosocomial
pneumonia. Crit Care 2009;13(6):R200.
[149] Goldstein I, Wallet F, Nicolas-Robin A, Ferrari F, Marquette CH, Rouby JJ. Lung
deposition and efficiency of nebulized amikacin during Escherichia coli
pneumonia in ventilated piglets. Am J Respir Crit Care Med
2002;166(10):1375–81.
[150] Goldstein I, Wallet F, Robert J, Becquemin MH, Marquette CH, Rouby JJ. Lung
tissue concentrations of nebulized amikacin during mechanical ventilation in
piglets with healthy lungs. Am J Respir Crit Care Med 2002;165(2):171–5.
M. Leone et al. / Anaesth Crit Care Pain Med 37 (2018) 83–9898[151] Lu Q, Girardi C, Zhang M, Bouhemad B, Louchahi K, Petitjean O, et al.
Nebulized and intravenous colistin in experimental pneumonia caused by
Pseudomonas aeruginosa. Intensive Care Med 2010;36(7):1147–55.
[152] Kruger P, Bailey M, Bellomo R, Cooper DJ, Harward M, Higgins A, et al., ANZ-
STATInS Investigators – ANZICS Clinical Trials Group. A multicenter random-
ized trial of atorvastatin therapy in intensive care patients with severe sepsis.
Am J Respir Crit Care Med 2013;187(7):743–50.
[153] Kruger PS, Harward ML, Jones MA, Joyce CJ, Kostner KM, Roberts MS, et al.
Continuation of statin therapy in patients with presumed infection: a ran-
domized controlled trial. Am J Respir Crit Care Med 2011;183(6):774–81.
[154] Novack V, Eisinger M, Frenkel A, Terblanche M, Adhikari NK, Douvdevani A,
et al. The effects of statin therapy on inflammatory cytokines in patients with
bacterial infections: a randomized double-blind placebo controlled clinical
trial. Intensive Care Med 2009;35(7):1255–60.
[155] Papazian L, Roch A, Charles PE, Penot-Ragon C, Perrin G, Roulier P, et al.,
STATIN-VAP Study Group. Effect of statin therapy on mortality in patients
with ventilator-associated pneumonia: a randomized clinical trial. JAMA
2013;310(16):1692–700.[156] Patel JM, Snaith C, Thickett DR, Linhartova L, Melody T, Hawkey P, et al.
Randomized double-blind placebo-controlled trial of 40 mg/day of atorvas-
tatin in reducing the severity of sepsis in ward patients (ASEPSIS Trial). Crit
Care 2012;16(6):R231.
[157] Wan YD, Sun TW, Kan QC, Guan FX, Zhang SG. Effect of statin therapy on
mortality from infection and sepsis: a meta-analysis of randomized and
observational studies. Crit Care 2014;18(2):R71.
[158] Bruyere R, Vigneron C, Prin S, Pechinot A, Quenot JP, Aho S, et al. Impact of
prior statin therapy on the outcome of patients with suspected ventilator-
associated pneumonia: an observational study. Crit Care 2014;18(2):R83.
[159] Que YA, Lazar H, Wolff M, François B, Laterre PF, Mercier E, et al. Assessment
of panobacumab as adjunctive immunotherapy for the treatment of nosoco-
mial Pseudomonas aeruginosa pneumonia. Eur J Clin Microbiol Infect Dis
2014;33(10):1861–7.
[160] Lu Q, Rouby JJ, Laterre PF, Eggimann P, Dugard A, Giamarellos-Bourboulis EJ,
et al. Pharmacokinetics and safety of panobacumab: specific adjunctive
immunotherapy in critical patients with nosocomial Pseudomonas aerugi-
nosa O11 pneumonia. J Antimicrob Chemother 2011;66(5):1110–6.
